https://scholars.lib.ntu.edu.tw/handle/123456789/470378
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | YU-YUN SHAO | en_US |
dc.contributor.author | KUAN-TING KUO | en_US |
dc.contributor.author | Hu F.-C. | en_US |
dc.contributor.author | YEN-SHEN LU | en_US |
dc.contributor.author | CHIUN-SHENG HUANG | en_US |
dc.contributor.author | JAU-YU LIAU | en_US |
dc.contributor.author | Lee W.-C. | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | WEN-HUNG KUO | en_US |
dc.contributor.author | KING-JEN CHANG | en_US |
dc.contributor.author | CHING-HUNG LIN | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.creator | Shao Y.-Y.;Kuo K.-T.;Hu F.-C.;Lu Y.-S.;Huang C.-S.;Jau-Yu Liau;Lee W.-C.;Hsu C.;Kuo W.-H.;Chang K.-J.;Lin C.-H.;Cheng A.-L. | - |
dc.date.accessioned | 2020-03-05T06:28:44Z | - |
dc.date.available | 2020-03-05T06:28:44Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951241525&doi=10.1093%2fjjco%2fhyp184&partnerID=40&md5=b0b4679eca06c9993866930317fbde99 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/470378 | - |
dc.description.abstract | Objective: We studied tau and excision repair cross-complementing 1 expression to evaluate their predictive values in advanced breast carcinoma patients. Methods: Patients treated with paclitaxel and cisplatin as the first-line chemotherapy for locally advanced or metastatic breast cancer were enrolled. The expression levels of tau and excision repair cross-complementing 1 were assessed by immunohistochemistry and examined for their associations with treatment response and survival. Results: Fifty-four patients were included in this study. Despite the strong association between tau expression and lower histological grade and estrogen receptor expression, tau expression remained an independent predictor for a lower response rate in multivariate analysis (odd ratio = 0.24, P = 0.02). However, tau expression was a predictor for longer overall survival in both univariate analysis (median, 57.5 vs. 30.4 months, P = 0.02) and multivariate analysis (hazard ratio = 0.36, P = 0.008). Excision repair cross-complementing 1 was not associated with treatment response or overall survival. Conclusions: Tau expression but not excision repair cross-complementing 1 in advanced breast cancer predicts poor response to combination chemotherapy of paclitaxel and cisplatin. However, tau expression is significantly associated with longer overall survival. ? The Author (2010). Published by Oxford University Press. All rights reserved. | - |
dc.relation.ispartof | Japanese Journal of Clinical Oncology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | cisplatin; estrogen receptor; excision repair cross complementing protein 1; hormone; paclitaxel; progesterone receptor; tau protein; antineoplastic agent; cisplatin; DNA binding protein; endonuclease; ERCC1 protein, human; paclitaxel; tau protein; tumor marker; adjuvant therapy; adult; advanced cancer; aged; article; breast carcinoma; cancer adjuvant therapy; cancer combination chemotherapy; cancer grading; clear cell carcinoma; drug dose regimen; drug dose sequence; gene expression; human; immunohistochemistry; low drug dose; major clinical study; mucinous carcinoma; multiple cycle treatment; overall survival; prediction; prognosis; survival time; treatment response; biosynthesis; breast tumor; disease free survival; drug resistance; female; genetics; Kaplan Meier method; metabolism; middle aged; phase 2 clinical trial; retrospective study; treatment outcome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Immunohistochemistry; Kaplan-Meiers Estimate; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; tau Proteins; Treatment Outcome; Tumor Markers, Biological | - |
dc.title | Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1093/jjco/hyp184 | - |
dc.identifier.pmid | 20085902 | - |
dc.identifier.scopus | 2-s2.0-77951241525 | - |
dc.relation.pages | 286-293 | - |
dc.relation.journalvolume | 40 | - |
dc.relation.journalissue | 4 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Pathology | - |
crisitem.author.dept | Pathology-NTUH | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Clinical Trial Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Pathology | - |
crisitem.author.dept | Pathology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.orcid | 0000-0002-3657-1652 | - |
crisitem.author.orcid | 0000-0001-7461-1291 | - |
crisitem.author.orcid | 0000-0002-6557-211X | - |
crisitem.author.orcid | 0000-0002-1336-3850 | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.orcid | 0000-0002-9881-4605 | - |
crisitem.author.orcid | 0000-0001-9811-3422 | - |
crisitem.author.orcid | 0000-0003-2403-4056 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。